General Information of Drug Transporter (DT)
DT ID DTD0241 Transporter Info
Gene Name SLC27A4
Transporter Name Long-chain fatty acid transport protein 4
Gene ID
10999
UniProt ID
Q6P1M0
Post-Translational Modification of This DT
Overview ofSLC27A4 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-Acetylation X-Malonylation X-Oxidation X-Phosphorylation X-Phosphorylation X-S-nitrosylation X-Sulfoxidation X-Ubiquitination X-Ubiquitination X: Amino Acid

Acetylation

  Lysine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC27A4 [1]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

471

Experimental Method

Co-Immunoprecipitation

Detailed Description

Acetylation at SLC27A4 Lysine 471 has the potential to affect its expression or activity.

  PTM Phenomenon2

Have the potential to influence SLC27A4 [1]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

603

Experimental Method

Co-Immunoprecipitation

Detailed Description

Acetylation at SLC27A4 Lysine 603 has the potential to affect its expression or activity.

Malonylation

  Lysine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC27A4 [2]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

454

Experimental Method

Co-Immunoprecipitation

Detailed Description

Malonylation at SLC27A4 Lysine 454 has the potential to affect its expression or activity.

  PTM Phenomenon2

Have the potential to influence SLC27A4 [2]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

471

Experimental Method

Co-Immunoprecipitation

Detailed Description

Malonylation at SLC27A4 Lysine 471 has the potential to affect its expression or activity.

Oxidation

  Cystine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC27A4 [3]

Role of PTM

Potential impacts

Modified Residue

Cystine

Modified Location

323

Experimental Method

Co-Immunoprecipitation

Detailed Description

Oxidation at SLC27A4 Cystine 323 has the potential to affect its expression or activity.

Phosphorylation

  Serine

          5 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC27A4 [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

14

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Serine 14 has the potential to affect its expression or activity.

  PTM Phenomenon2

Have the potential to influence SLC27A4 [5]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

82

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Serine 82 has the potential to affect its expression or activity.

  PTM Phenomenon3

. [6]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

373

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Serine 373 has the potential to affect its expression or activity.

  PTM Phenomenon4

Have the potential to influence SLC27A4 [7], [8]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

411

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Serine 411 has the potential to affect its expression or activity.

  PTM Phenomenon5

Have the potential to influence SLC27A4 [9], [10]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

555

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Serine 555 has the potential to affect its expression or activity.

  Threonine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC27A4 [5]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

83

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Threonine 83 has the potential to affect its expression or activity.

  Tyrosine

          4 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

. [6]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

243

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Tyrosine 243 has the potential to affect its expression or activity.

  PTM Phenomenon2

. [6]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

245

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Tyrosine 245 has the potential to affect its expression or activity.

  PTM Phenomenon3

Have the potential to influence SLC27A4 [8], [11]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

414

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Tyrosine 414 has the potential to affect its expression or activity.

  PTM Phenomenon4

Have the potential to influence SLC27A4 [12]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

463

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC27A4 Tyrosine 463 has the potential to affect its expression or activity.

S-nitrosylation

  Cystine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC27A4 [13]

Role of PTM

Potential impacts

Modified Residue

Cystine

Modified Location

338

Experimental Method

Co-Immunoprecipitation

Detailed Description

S-nitrosylation (-SNO) at SLC27A4 Cystine 338 has the potential to affect its expression or activity.

  PTM Phenomenon2

Have the potential to influence SLC27A4 [13]

Role of PTM

Potential impacts

Modified Residue

Cystine

Modified Location

560

Experimental Method

Co-Immunoprecipitation

Detailed Description

S-nitrosylation (-SNO) at SLC27A4 Cystine 560 has the potential to affect its expression or activity.

Sulfoxidation

  Methionine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

Have the potential to influence SLC27A4 [14]

Role of PTM

Potential impacts

Modified Residue

Methionine

Modified Location

426

Experimental Method

Co-Immunoprecipitation

Detailed Description

Sulfoxidation at SLC27A4 Methionine 426 has the potential to affect its expression or activity.

Ubiquitination

  Lysine

        10 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon1

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

90

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 90 has the potential to affect its expression or activity.

  PTM Phenomenon2

. [6]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

90

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 90 has the potential to affect its expression or activity.

  PTM Phenomenon3

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

475

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 475 has the potential to affect its expression or activity.

  PTM Phenomenon4

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

571

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 571 has the potential to affect its expression or activity.

  PTM Phenomenon5

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

571

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 571 has the potential to affect its expression or activity.

  PTM Phenomenon6

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

595

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 595 has the potential to affect its expression or activity.

  PTM Phenomenon7

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

595

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 595 has the potential to affect its expression or activity.

  PTM Phenomenon8

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

598

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 598 has the potential to affect its expression or activity.

  PTM Phenomenon9

. [15]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

598

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 598 has the potential to affect its expression or activity.

  PTM Phenomenon10

Have the potential to influence SLC27A4 [16]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

622

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC27A4 Lysine 622 has the potential to affect its expression or activity.
References
1 Quantitative Proteomic Atlas of Ubiquitination and Acetylation in the DNA Damage Response. Mol Cell. 2015 Sep 3;59(5):867-81.
2 Proteomic and Biochemical Studies of Lysine Malonylation Suggest Its Malonic Aciduria-associated Regulatory Role in Mitochondrial Function and Fatty Acid Oxidation. Mol Cell Proteomics. 2015 Nov;14(11):3056-71.
3 A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell. 2020 Mar 5;180(5):968-983.e24.
4 Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
5 Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res. 2013 Jun 7;12(6):2414-21.
6 15 years of PhosphoSitePlus?: integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 2019;47(D1):D433-D441.
7 Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun. 2017 Mar 28;8:14864.
8 Phosphoproteomic and Functional Analyses Reveal Sperm-specific Protein Changes Downstream of Kappa Opioid Receptor in Human Spermatozoa. Mol Cell Proteomics. 2019 Mar 15;18(Suppl 1):S118-S131.
9 Offline pentafluorophenyl (PFP)-RP prefractionation as an alternative to high-pH RP for comprehensive LC-MS/MS proteomics and phosphoproteomics. Anal Bioanal Chem. 2017 Jul;409(19):4615-4625.
10 Protein kinase C-alpha interaction with F0F1-ATPase promotes F0F1-ATPase activity and reduces energy deficits in injured renal cells. J Biol Chem. 2015 Mar 13;290(11):7054-66.
11 Deep Phosphotyrosine Proteomics by Optimization of Phosphotyrosine Enrichment and MS/MS Parameters. J Proteome Res. 2017 Feb 3;16(2):1077-1086.
12 Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder. Nat Chem Biol. 2016 Nov;12(11):959-966.
13 Proteome-wide detection of S-nitrosylation targets and motifs using bioorthogonal cleavable-linker-based enrichment and switch technique. Nat Commun. 2019 May 16;10(1):2195.
14 Redox proteomics of protein-bound methionine oxidation. Mol Cell Proteomics. 2011 May;10(5):M110.006866.
15 ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. Nucleic Acids Res. 2018;46(D1):D901-D910.
16 Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011 Oct 21;44(2):325-40.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.